Direkt zum Inhalt

Owner only: item control page
Stupp, Roger ; Hegi, Monika E. ; Mason, Warren P. ; van den Bent, Martin J. ; Taphoorn, Martin J. B. ; Janzer, Robert C. ; Ludwin, Samuel K. ; Allgeier, Anouk ; Fisher, Barbara ; Belanger, Karl ; Hau, Peter ; Brandes, Alba A. ; Gijtenbeek, Johanna ; Marosi, Christine ; Vecht, Charles J. ; Mokhtari, Karima ; Wesseling, Pieter ; Villa, Salvador ; Eisenhauer, Elizabeth ; Gorlia, Thierry ; Weller, Michael ; Lacombe, Denis ; Cairncross, J. Gregory ; Mirimanoff, René-Olivier

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Stupp, Roger, Hegi, Monika E. , Mason, Warren P., van den Bent, Martin J. , Taphoorn, Martin J. B., Janzer, Robert C., Ludwin, Samuel K., Allgeier, Anouk, Fisher, Barbara, Belanger, Karl, Hau, Peter, Brandes, Alba A. , Gijtenbeek, Johanna, Marosi, Christine, Vecht, Charles J., Mokhtari, Karima, Wesseling, Pieter , Villa, Salvador , Eisenhauer, Elizabeth, Gorlia, Thierry, Weller, Michael, Lacombe, Denis, Cairncross, J. Gregory and Mirimanoff, René-Olivier (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The lancet oncology 10 (5), pp. 459-466.

Date of publication of this fulltext: 15 Jan 2014 10:55
Article



Involved Institutions


Details

Item typeArticle
Journal or Publication TitleThe lancet oncology
Publisher:ELSEVIER SCIENCE INC
Place of Publication:NEW YORK
Volume:10
Number of Issue or Book Chapter:5
Page Range:pp. 459-466
Date2009
Additional Information (public)European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group
InstitutionsMedicine > Lehrstuhl für Neurologie
Identification Number
ValueType
19410186PubMed ID
10.1016/S1470-2045(09)70025-7DOI
Classification
NotationType
Antineoplastic Agents, Alkylating/therapeutic useMESH
Brain Neoplasms/radiotherapyMESH
Combined Modality TherapyMESH
DNA MethylationMESH
DNA Modification Methylases/geneticsMESH
DNA Repair Enzymes/geneticsMESH
Dacarbazine/therapeutic useMESH
Disease ProgressionMESH
FemaleMESH
Follow-Up StudiesMESH
Glioblastoma/radiotherapyMESH
HumansMESH
MaleMESH
Middle AgedMESH
PrognosisMESH
Promoter Regions, GeneticMESH
Survival AnalysisMESH
Survival RateMESH
Tumor Suppressor Proteins/geneticsMESH
KeywordsNEWLY-DIAGNOSED GLIOBLASTOMA; RECURSIVE PARTITIONING ANALYSIS; MGMT PROMOTER METHYLATION; CONTROLLED CLINICAL-TRIAL; ASPARTIC ACID PEPTIDE; MALIGNANT GLIOMA; PROGNOSTIC-FACTORS; ACCELERATED RADIOTHERAPY; ONCOLOGY-GROUP; MULTIFORME;
Dewey Decimal Classification600 Technology > 610 Medical sciences Medicine
StatusPublished
RefereedYes, this version has been refereed
Created at the University of RegensburgUnknown
Item ID29262

Export bibliographical data

Owner only: item control page

nach oben